0102030405
Orforglipron CAS No. 2212020-52-3 Pharmaceutical Raw Material
02
introduce
introduce
Orforglipron is a potent oral non-peptide GLP-1 receptor agonist and core pharmaceutical API. It mimics GLP-1 physiological functions to regulate blood glucose and body weight.
Under clinical development for Type 2 Diabetes Mellitus (T2DM) and obesity management, our products comply with strict international standards to ensure high purity, stable efficacy, and reliable supply.
02
Physical and chemical properties
Orforglipron exhibits key physical and chemical characteristics supporting its pharmaceutical and research applications, as follows:
- Density: 1.50±0.1 g/cm³
- Storage: Stored in -20 °C
- Solubility: Freely soluble in DMSO (125 mg/mL, 141.57 mM)
- Density: 1.50±0.1 g/cm³
- Storage: Stored in -20 °C
- Solubility: Freely soluble in DMSO (125 mg/mL, 141.57 mM)
1. More Convenient Administration
As an oral non-peptide GLP-1 receptor agonist, it only needs to be taken orally once a day without restrictions on food or water intake. Compared with mainstream subcutaneous injection GLP-1 analogues, improves the convenience of medication, making it more suitable for long-term medication users.
As an oral non-peptide GLP-1 receptor agonist, it only needs to be taken orally once a day without restrictions on food or water intake. Compared with mainstream subcutaneous injection GLP-1 analogues, improves the convenience of medication, making it more suitable for long-term medication users.
2. Targeted Action
Its hypoglycemic and weight-loss effects are comparable to other GLP-1 receptor agonists, which can significantly reduce the glycated hemoglobin (HbA1c) level and body weight of patients with type 2 diabetes. It precisely regulates blood glucose and body weight by enhancing glucose-dependent insulin secretion, delaying gastric emptying, inhibiting food intake and improving body energy balance.
Its hypoglycemic and weight-loss effects are comparable to other GLP-1 receptor agonists, which can significantly reduce the glycated hemoglobin (HbA1c) level and body weight of patients with type 2 diabetes. It precisely regulates blood glucose and body weight by enhancing glucose-dependent insulin secretion, delaying gastric emptying, inhibiting food intake and improving body energy balance.
3. Good Safety and Tolerability
No adverse events inconsistent with other GLP-1 receptor agonists have been found in clinical studies, ensuring medication safety, and it is suitable as a treatment option for patients with type 2 diabetes and obesity. It has characteristics conducive to oral administration, can exert stable efficacy without complex medication coordination.
1. Metabolic Disease Treatment
(1) Potential treatment for Type 2 Diabetes Mellitus (T2DM) in adults to improve glycemic control.
(2) Potential management of obesityor overweight with weight-related comorbidities.
2. Biomedical Research
Tool compound for studying oral GLP-1 receptor signaling pathways and development of non-peptide metabolic disease therapeutics.
(1) Potential treatment for Type 2 Diabetes Mellitus (T2DM) in adults to improve glycemic control.
(2) Potential management of obesityor overweight with weight-related comorbidities.
2. Biomedical Research
Tool compound for studying oral GLP-1 receptor signaling pathways and development of non-peptide metabolic disease therapeutics.
We implement strict full-process quality control, with each batch of Orforglipron undergoing rigorous testing of key indicators including purity, solubility, stability, and chiral purity to meet standards.
Equipped with a stable raw material supply chain and advanced synthetic facilities, we ensure continuous large-scale supply. Our professional technical team provides tailored services, including formulation optimization, application guidance, and post-sales technical support for clinical and research needs.
Equipped with a stable raw material supply chain and advanced synthetic facilities, we ensure continuous large-scale supply. Our professional technical team provides tailored services, including formulation optimization, application guidance, and post-sales technical support for clinical and research needs.
As a pioneering oral non-peptide GLP-1 receptor agonist, Orforglipron addresses unmet needs in metabolic disease treatment, offering convenience and efficacy for patients with T2DM and obesity. With its unique oral advantage, proven therapeutic potential, exceptional quality, and reliable supply capacity, we are committed to providing high-quality Orforglipron API and professional services for global pharmaceutical companies, research institutions, and clinical applications.
Choose our Orforglipron to meet your needs in pharmaceutical formulation, metabolic disease research, and clinical development. Contact us for more product details and cooperation support.
Choose our Orforglipron to meet your needs in pharmaceutical formulation, metabolic disease research, and clinical development. Contact us for more product details and cooperation support.